Clinical trial NCT02662348 - References

Pancreatic Cancer — T Cell Mediated Adaptive Therapy for Her2-positive Neoplasms of Digestive System

Citation(s)

•   Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, Cabaret V, Fermeaux V, Bertheau P, Garnier J, Jeannin JF, Coudert B
  Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer. 2006 Jan 30;94(2):259-67.
•   Brown CE, Wright CL, Naranjo A, Vishwanath RP, Chang WC, Olivares S, Wagner JR, Bruins L, Raubitschek A, Cooper LJ, Jensen MC
  Biophotonic cytotoxicity assay for high-throughput screening of cytolytic killing. J Immunol Methods. 2005 Feb;297(1-2):39-52. Epub 2005 Jan 22.
•   Camilleri-Broët S, Hardy-Bessard AC, Le Tourneau A, Paraiso D, Levrel O, Leduc B, Bain S, Orfeuvre H, Audouin J, Pujade-Lauraine E; GINECO group
  HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group. Ann Oncol. 2004 Jan;15(1):104-12.
•   Davol PA, Smith JA, Kouttab N, Elfenbein GJ, Lum LG
  Anti-CD3 x anti-HER2 bispecific antibody effectively redirects armed T cells to inhibit tumor development and growth in hormone-refractory prostate cancer-bearing severe combined immunodeficient beige mice. Clin Prostate Cancer. 2004 Sep;3(2):112-21.
•   Fu X, Tao L, Rivera A, Williamson S, Song XT, Ahmed N, Zhang X
  A simple and sensitive method for measuring tumor-specific T cell cytotoxicity. PLoS One. 2010 Jul 29;5(7):e11867. doi: 10.1371/journal.pone.0011867.
•   Grabert RC, Cousens LP, Smith JA, Olson S, Gall J, Young WB, Davol PA, Lum LG
  Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation. Clin Cancer Res. 2006 Jan 15;12(2):569-76.
•   Han H, Ma J, Zhang K, Li W, Liu C, Zhang Y, Zhang G, Ma P, Wang L, Zhang G, Tao H, Gao B
  Bispecific anti-CD3 x anti-HER2 antibody mediates T cell cytolytic activity to HER2-positive colorectal cancer in vitro and in vivo. Int J Oncol. 2014 Dec;45(6):2446-54. doi: 10.3892/ijo.2014.2663. Epub 2014 Sep 18.
•   Hudis CA
  Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med. 2007 Jul 5;357(1):39-51. Review.
•   Janjigian YY, Werner D, Pauligk C, Steinmetz K, Kelsen DP, Jäger E, Altmannsberger HM, Robinson E, Tafe LJ, Tang LH, Shah MA, Al-Batran SE
  Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol. 2012 Oct;23(10):2656-62. Epub 2012 Jun 11.
•   Jørgensen JT, Hersom M
  HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature. J Cancer. 2012;3:137-44. doi: 10.7150/jca.4090. Epub 2012 Mar 12.
•   Jørgensen JT
  Targeted HER2 treatment in advanced gastric cancer. Oncology. 2010;78(1):26-33. doi: 10.1159/000288295. Epub 2010 Feb 25.
•   Kountourakis P, Pavlakis K, Psyrri A, Rontogianni D, Xiros N, Patsouris E, Pectasides D, Economopoulos T
  Clinicopathologic significance of EGFR and Her-2/neu in colorectal adenocarcinomas. Cancer J. 2006 May-Jun;12(3):229-36.
•   Krähn G, Leiter U, Kaskel P, Udart M, Utikal J, Bezold G, Peter RU
  Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer. Eur J Cancer. 2001 Jan;37(2):251-9.
•   Lum LG, Rathore R, Cummings F, Colvin GA, Radie-Keane K, Maizel A, Quesenberry PJ, Elfenbein GJ
  Phase I/II study of treatment of stage IV breast cancer with OKT3 x trastuzumab-armed activated T cells. Clin Breast Cancer. 2003 Aug;4(3):212-7.
•   Ma J, Han H, Liu D, Li W, Feng H, Xue X, Wu X, Niu G, Zhang G, Zhao Y, Liu C, Tao H, Gao B
  HER2 as a promising target for cytotoxicity T cells in human melanoma therapy. PLoS One. 2013 Aug 27;8(8):e73261. doi: 10.1371/journal.pone.0073261. eCollection 2013. Erratum in: PLoS One. 2013;8(9). doi:10.1371/annotation/611f44b7-e349-4e7f-9dfe-bdfc724c2f4c.
•   Ma P, He Q, Li W, Li X, Han H, Jin M, Liu C, Tao H, Ma J, Gao B
  Anti-CD3 x EGFR bispecific antibody redirects cytokine-induced killer cells to glioblastoma in vitro and in vivo. Oncol Rep. 2015 Nov;34(5):2567-75. doi: 10.3892/or.2015.4233. Epub 2015 Aug 28.
•   Mann M, Sheng H, Shao J, Williams CS, Pisacane PI, Sliwkowski MX, DuBois RN
  Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology. 2001 Jun;120(7):1713-9.
•   Mimura K, Kono K, Hanawa M, Kanzaki M, Nakao A, Ooi A, Fujii H
  Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma. Clin Cancer Res. 2005 Jul 1;11(13):4898-904.
•   Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J
  Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. 2001 Jun 15;61(12):4744-9.
•   Pagni F, Zannella S, Ronchi S, Garanzini C, Leone BE
  HER2 status of gastric carcinoma and corresponding lymph node metastasis. Pathol Oncol Res. 2013 Jan;19(1):103-9. doi: 10.1007/s12253-012-9564-2. Epub 2012 Aug 21.
•   Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN
  The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009 Apr;14(4):320-68. doi: 10.1634/theoncologist.2008-0230. Epub 2009 Apr 3. Review.
•   Schuell B, Gruenberger T, Scheithauer W, Zielinski Ch, Wrba F
  HER 2/neu protein expression in colorectal cancer. BMC Cancer. 2006 May 8;6:123.
•   Takenaka M, Hanagiri T, Shinohara S, Kuwata T, Chikaishi Y, Oka S, Shigematsu Y, Nagata Y, Shimokawa H, Nakagawa M, Uramoto H, So T, Tanaka F
  The prognostic significance of HER2 overexpression in non-small cell lung cancer. Anticancer Res. 2011 Dec;31(12):4631-6.
•   Whenham N, D'Hondt V, Piccart MJ
  HER2-positive breast cancer: from trastuzumab to innovatory anti-HER2 strategies. Clin Breast Cancer. 2008 Feb;8(1):38-49. doi: 10.3816/CBC.2008.n.002. Review.
•   Zhang G, Liu R, Zhu X, Wang L, Ma J, Han H, Wang X, Zhang G, He W, Wang W, Liu C, Li S, Sun M, Gao B
  Retargeting NK-92 for anti-melanoma activity by a TCR-like single-domain antibody. Immunol Cell Biol. 2013 Nov-Dec;91(10):615-24. doi: 10.1038/icb.2013.45. Epub 2013 Oct 8.
•   Zitron IM, Thakur A, Norkina O, Barger GR, Lum LG, Mittal S
  Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies. BMC Cancer. 2013 Feb 22;13:83. doi: 10.1186/1471-2407-13-83.

T Cell Mediated Adaptive Therapy for Her2-positive Neoplasms of Digestive System

Details for clinical trial NCT02662348